Developing a New Class of Intracellular Targeted Therapeutics

Ashvattha Therapeutics are harnessing the power of Hydroxyl Dendrimers (HDs) to create a new class of precision medicine to heal patients.

Welcome to Ashvattha

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel hydroxyl dendrimer (HD) therapeutics (HDTs) to treat unmet medical needs in oncology, ophthalmology, and inflammatory diseases. We believe that HDTs will become the future of targeted therapeutics and unlock new levels of patient care.

We are developing immune-oncology HD therapeutics in serious unmet needs leveraging our ability to target tumor associated macrophages (TAMs)

We have designed and optimized an HDT that precisely targets reactive macrophages and retinal pigment epithelial cells (RPEs) after systemic administration

OP-101 selectively targets pro-inflammatory macrophages and microglia responsible for excessive cytokine production in severe COVID-19 patients

Latest News

Neurologists test novel compound for lung and brain injury in severe COVID-19 patients (UT Health News)

Neurologists are researching whether a novel immunomodulatory treatment, OP-101, an investigational compound developed by Ashvattha Therapeutics, can dampen lung and brain injury in hospitalized COVID-19 patients through a clinical trial at The University of Texas Health Science Center at Houston.

Ashvattha Therapeutics Presents Transformative Anti-Angiogenesis Treatment for Retinal Disorders at ARVO 2021

Ashvattha announced the presentation of a virtual poster supporting the development of its proprietary HDT, D-4517, for treatment of AMD at the 2021 ARVO Annual Meeting.

Ashvattha Therapeutics Announces Collaboration with Stanford University for Preclinical Development of a Novel Neuroimaging Agent, OP-801

Ashvattha initiates a preclinical proof of concept study for OP-801 imaging of neuroinflammation. This Investigational New Drug (IND)-enabling research will be conducted in collaboration with a team of researchers at the Stanford University School of Medicine led by Michelle James, Ph.D., Assistant Professor of Radiology and Neurology.

Ashvattha Therapeutics Selected to Present Late-Breaking Poster Presentation on Use of Novel Hepatocyte Targeted Hydroxyl Dendrimer Therapeutic at The Liver Meeting 2020

Ashvattha Therapeutics announced data from a late-breaking presentation at The Liver Meeting Digital Experience 2020 of the American Association for the Study of Liver Diseases (AASLD), held virtually November 13-16, 2020.